

1050
RECEIVED

JUL 31 2002

TECH CENTER 1600/290

HOWREY SIMON ARNOLD & WHITE, LLP

301 Ravenswood Avenue

Box 34

Menlo Park, CA 94025

(650) 463-8109



FORM PTO-1083
Box Non-Fee Amendment
THE COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Attorney Docket No.00800.0051.CNUS03

Sir:

In re application of: Emil D. KAKKIS
Application Serial No. 09/993,241
Filed: November 13, 2001
For: METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF RECOMBINANT α -L-IDURONIDASE

Transmitted herewith are the following:

1. PTO Form 1083;
2. Request for Transferring Previous Filed Sequence Information;
3. Preliminary Amendment;
4. Clean Version with Amendments Incorporated;
5. Marked-up Version to Show Changes Made;
6. Return receipt postcard.

No Additional Claim Fee is required.

The claim fee has been calculated as shown below:


	(Col. 1)		(Col. 2)	(Col. 3)
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra
Total Claims		MINUS		= 0
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM				

SMALL ENTITY	
Rate	Addit. Fee
x 9 =	\$ 0.00
X 42 =	\$.00
+135 =	\$.00
Total Addit. Fee	\$.00

OTHER THAN A SMALL ENTITY	
Rate	Addit. Fee
x 18 =	\$ 00.00
x 84 =	\$ 00.00
+ 270 =	\$ 00.00
TOTAL	\$ 00.00

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing Attorney Docket No.: 00800.0051.00US00.

Date: July 24, 2002



Albert P. Halluin (Reg. No. 25,227)
Robin C. Chiang (Reg. No. 46,619)

EXPRESS MAILING NO.: EL615211515US

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Emil D. KAKKIS

Application No.: 09/993,241

Filed: November 13, 2001

For: **METHODS FOR TREATING DISEASES
CAUSED BY DEFICIENCIES OF
RECOMBINANT α -L-IDURONIDASE**



Art Unit: 1652

Examiner: Not yet assigned

Attorney Docket No: 00800.0051.CNUS03

8/2

M.J.S

8/6/02

PRELIMINARY AMENDMENT

BOX: NON-FEE AMENDMENT

Director of the U.S. Patent and Trademark Office
Washington, D.C. 20231

Sir:

AMENDMENT

In the Sequence Listing

Please replace the Sequence Listing with the attached Sequence Listing (7 pages), titled Clean Version with Amendments Incorporated.

REMARKS

The Amendments

The amendment is to correct typographic errors.

Support for the amended Sequence Listing is found, for example, in Figure 1 (the amino acid sequence of SEQ ID NOs: 1 and 2 corresponds to the amino acid sequence of "ORF RF[1]").

Applicant request amendment of SEQ ID NOs:1 and 2 in order to conform the Sequence Listing of the instant application with the Sequence Listing submitted in the parent patent application, U.S. Application Serial No. 09/439,923, filed November 12, 1999 (to be issued on July 30, 2002 as U.S. Patent No. 6,426,208) (hereafter the "923 Application") of this instant application.

As indicated in the Version with Markings to Show Changes Made, the difference